EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Rebastinib inhibits FoxO1 activity and reduces dexamethasone-induced atrophy and its-related gene expression in cultured myotubes

Tomoki Sato, Akihito Morita, Yui Watanabe, Yumi Naito, Haruka Kawaji, Takumi Nakagawa, Hiroki Hamaguchi, Yasuko Manabe, Nobuharu L Fujii, Naohisa Ogo, Akira Asai, Yasutomi Kamei und 1 weitere

The Journal of Physiological Sciences · 2025

DOI: 10.1016/j.jphyss.2025.100012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Physiological Sciences, 2025. Verfasst von Tomoki Sato und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nutritional Biochemistry, Graduate School of Nutritional and Environmental Sciences, University of Shizuoka, Shizuoka, Japan. Hauptthemen laut MEDLINE: Dexamethasone, Muscle Fibers, Skeletal, Muscular Atrophy, Forkhead Box Protein O1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shizuoka University, Council for Science Technology and Innovation, National Agriculture and Food Research Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FoxO1, a transcription factor, is upregulated in skeletal muscle during atrophy and inactivation of FoxO1 is a potential strategy to prevent muscle loss. This study identified Rebastinib as a potent suppressor of FoxO1 activity among protein kinase inhibitors. To determine whether Rebastinib inhibits atrophy-related ubiquitin ligases gene expression and mitigates atrophy in mouse skeletal muscle-derived cells, we investigated its protective effects of the compound against dexamethasone (DEX)-induced muscle atrophy using C2C12 myotubes. Rebastinib inhibited the DEX-induced upregulation of atrogin-1 and MuRF-1 mRNA, and atrogin-1 protein. Rebastinib also suppressed protein degradation and increased myotube diameter in DEX-treated C2C12 myotubes. Additionally, Rebastinib ameliorated the DEX- and cachexia-induced reduction in contractile force generation. Although the precise mechanisms underlying the action of Rebastinib against muscle atrophy and its efficacy in vivo remains to be elucidated, this compound shows great potential as a therapeutic agent for muscle atrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneMuscle Fibers, SkeletalMuscular AtrophyForkhead Box Protein O1AnimalsMiceUbiquitin-Protein LigasesMuscle ProteinsTripartite Motif ProteinsCell LineSKP Cullin F-Box Protein LigasesMuscle, Skeletal

Stichwörter der Autor:innen

Cancer cachexiaDexamethasoneFoxO1 inhibitionMuscle atrophyRebastinib

Substanzen

DexamethasoneForkhead Box Protein O1Ubiquitin-Protein LigasesFoxo1 protein, mouseMuscle ProteinsTripartite Motif ProteinsSKP Cullin F-Box Protein LigasesFbxo32 protein, mouseTrim63 protein, mouse

Autor:innen und Institutionen

  • Laboratory of Nutritional Biochemistry, Graduate School of Nutritional and Environmental Sciences, University of Shizuoka, Shizuoka, Japan.
  • Department of Health Promotion Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Tokyo, Japan.
  • Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Laboratory of Molecular Nutrition, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan.
  • Laboratory of Nutritional Biochemistry, Graduate School of Nutritional and Environmental Sciences, University of Shizuoka, Shizuoka, Japan. Electronic address: miura@u-shizuoka-ken.ac.jp.

Förderung

  • Shizuoka University
  • Council for Science Technology and Innovation
  • National Agriculture and Food Research Organization
  • Bio-oriented Technology Research Advancement Institution
  • Swine Innovation Porc
  • Princess Takamatsu Cancer Research Fund
  • JST Adaptable and Seamless Technology Transfer Program Through Target-driven R and D

Zitieren

APA

Sato, T., Morita, A., Watanabe, Y., Naito, Y., Kawaji, H., Nakagawa, T., Hamaguchi, H., Manabe, Y., Fujii, N. L., Ogo, N., Asai, A., Kamei, Y., & Miura, S. (2025). Rebastinib inhibits FoxO1 activity and reduces dexamethasone-induced atrophy and its-related gene expression in cultured myotubes. The Journal of Physiological Sciences. https://doi.org/10.1016/j.jphyss.2025.100012

Vancouver

Sato T, Morita A, Watanabe Y, Naito Y, Kawaji H, Nakagawa T, et al. Rebastinib inhibits FoxO1 activity and reduces dexamethasone-induced atrophy and its-related gene expression in cultured myotubes. The Journal of Physiological Sciences. 2025. doi:10.1016/j.jphyss.2025.100012

BibTeX
@article{Sato2025,
  author = {Sato, Tomoki and Morita, Akihito and Watanabe, Yui and Naito, Yumi and Kawaji, Haruka and Nakagawa, Takumi and Hamaguchi, Hiroki and Manabe, Yasuko and Fujii, Nobuharu L and Ogo, Naohisa and Asai, Akira and Kamei, Yasutomi and Miura, Shinji},
  title = {Rebastinib inhibits FoxO1 activity and reduces dexamethasone-induced atrophy and its-related gene expression in cultured myotubes},
  journal = {The Journal of Physiological Sciences},
  year = {2025},
  doi = {10.1016/j.jphyss.2025.100012}
}
Kostenlos starten →